Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,(1aS,8S,8aR,8bS)- cas no:801-52-5

NameAzirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,(1aS,8S,8aR,8bS)-
CAS801-52-5
SynonymsAzirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethyl-,carbamate (ester) (8CI); Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-,[1aS-(1aa,8b,8aa,8ba)]-; ENT 50825; Methyl mitomycinC; Methylmitomycin; N-Methylmitomycin C; NCI 56410; NSC 56410; Porfiromycin;Porfiromycine; Regamycin; U 14743
Molecular FormulaC16H20 N4 O5
Molecular Weight348.40

refractive index1.672

Safety

 N-Methylmitomycin C (CAS NO.801-52-5) is poisonous by ingestion, intravenous, subcutaneous, and intraperitoneal routes. Human systemic effects by intravenous route: blood effects. Human mutation data reported. When N-Methylmitomycin C (CAS NO.801-52-5) is heated to decomposition, it emits toxic fumes of NO_x.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LDLo	oral	10mg/kg (10mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL) BLOOD: GRANULOCYTOPENIA	Antibiotics and Chemotherapy Vol. 11, Pg. 445, 1961.
human	TDLo	intravenous	1500ug/kg (1.5mg/kg)	BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA	Cancer Chemotherapy Reports, Part 1. Vol. 56, Pg. 615, 1972.
monkey	LD	oral	> 10mg/kg (10mg/kg)	BLOOD: GRANULOCYTOPENIA	Antibiotics and Chemotherapy Vol. 11, Pg. 445, 1961.
mouse	LD50	intraperitoneal	44mg/kg (44mg/kg)		Cancer Chemotherapy Reports. Vol. 30, Pg. 9, 1963.
mouse	LD50	intravenous	55mg/kg (55mg/kg)		Journal of Medicinal Chemistry. Vol. 14, Pg. 103, 1971.
mouse	LD50	oral	88660ug/kg (88.66mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse	LD50	subcutaneous	53500ug/kg (53.5mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rat	LD50	oral	68mg/kg (68mg/kg)		"Compounds Available for Fundamental Research, Volume II-6, Antibiotics, A Program of Upjohn Company Research Laboratory." Vol. 2(6), Pg. -, 1971.